Neoadjuvant treatment strategies for hepatocellular carcinoma

被引：15
|
作者：
Xu, Lei [1 ]
Chen, Lin [1 ]
Zhang, Wei [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, 1095 Jie Fang Ave, Wuhan 430030, Hubei, Peoples R China
来源：
WORLD JOURNAL OF GASTROINTESTINAL SURGERY | 2021年 / 13卷 / 12期
关键词：
Hepatocellular carcinoma; Neoadjuvant therapy; Prognosis; Indications; Contraindications; PORTAL-VEIN EMBOLIZATION; DRUG-ELUTING BEADS; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; GEMCITABINE PLUS OXALIPLATIN; RECURRENCE-FREE SURVIVAL; FATTY LIVER-DISEASE; INFERIOR VENA-CAVA; TRANSARTERIAL CHEMOEMBOLIZATION; Y-90; RADIOEMBOLIZATION; CONVENTIONAL CHEMOEMBOLIZATION;
D O I：
10.4240/wjgs.v13.i12.1550
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
The incidence of hepatocellular carcinoma (HCC) remains high globally. Surgical treatment is the best treatment for improving the prognosis of patients with HCC. Neoadjuvant therapy plays a key role in preventing tumor progression and even downstaging HCC. The liver transplantation rate and resectability rate have increased for neoadjuvant therapy. Neoadjuvant therapy is effective in different stages of HCC. In this review, we summarized the definition, methods, effects, indications and contraindications of neoadjuvant therapy in HCC, which have significance for guiding treatment.
引用
收藏
页码：1550 / 1566
页数：17
相关论文
共 50 条
  • [41] Multimodal Treatment Strategies in Patients Undergoing Surgery for Hepatocellular Carcinoma
    Lurje, Georg
    Lesurtel, Mickael
    Clavien, Pierre-Alain
    DIGESTIVE DISEASES, 2013, 31 (01) : 112 - 117
  • [42] Resection Strategies for Hepatocellular Carcinoma
    Wong, Tiffany Cho Lam
    Lo, Chung Mau
    SEMINARS IN LIVER DISEASE, 2013, 33 (03) : 273 - 281
  • [43] Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
    Christiana J. Crook
    Daneng Li
    Current Oncology Reports, 2023, 25 : 1191 - 1201
  • [44] Transplantation strategies for hepatocellular carcinoma
    Rauchfuss, F.
    Settmacher, U.
    CHIRURG, 2016, 87 (10): : 890 - 890
  • [45] Neoadjuvant therapy for hepatocellular carcinoma: Is there an optimal approach
    Almhanna, Khaldoun
    Kalmadi, Sujith
    Pelley, Robert
    Kim, Richard
    ONCOLOGY-NEW YORK, 2007, 21 (09): : 1116 - 1122
  • [46] Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma
    Vinita Akula
    Lily Chen
    Yusuf Acikgoz
    Katherine Klein
    Betul Gok Yavuz
    Lokman Cevik
    Tarik Demir
    Ashish Manne
    Ilyas Sahin
    Ahmed Kaseb
    Elshad Hasanov
    npj Precision Oncology, 9 (1)
  • [47] Strategies for the management of hepatocellular carcinoma
    Myron Schwartz
    Sasan Roayaie
    Manousos Konstadoulakis
    Nature Clinical Practice Oncology, 2007, 4 : 424 - 432
  • [48] Chemopreventive strategies in hepatocellular carcinoma
    Singh, Siddharth
    Singh, Preet Paul
    Roberts, Lewis R.
    Sanchez, William
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2014, 11 (01) : 45 - 54
  • [49] Strategies for the management of hepatocellular carcinoma
    Schwartz, Myron
    Roayaie, Sasan
    Konstadoulakis, Manousos
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (07): : 424 - 432
  • [50] Neoadjuvant immunotherapy for resectable hepatocellular carcinoma reply
    Marron, Thomas U.
    Schwartz, Myron E.
    Miller, Elizabeth
    Thanigaimani, Pradeep
    Lowy, Israel
    Thurston, Gavin
    Merad, Miriam
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (06): : 505 - 505
12345